Name: Ondansetron HCl
Brand: Selleck Chemicals
SKU: S1390
Availability: InStock
Rating: 5 (3 reviews)

Jump to

Quality Control

Batch: Purity: 99.88%

99.88

Related Targets	Adrenergic Receptor AChR COX Calcium Channel Histamine Receptor Dopamine Receptor GABA Receptor TRP Channel Cholinesterase (ChE) GluR
Other 5-HT Receptor Inhibitors	Serotonin Hydrochloride (5-HT HCl) WAY-100635 Maleate Puerarin SB269970 HCl Ketanserin BRL-15572 Dihydrochloride Nuciferine RS-127445 Flopropione Azacyclonol

Solubility

In vitro
Batch:

Water : 166 mg/mL

DMSO : 66 mg/mL (200.1 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 13 mg/mL

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.330mg/ml (1.00mM)	Taking the 1 mL working solution as an example, add 50 μL of 6.6 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.410mg/ml (1.24mM)	Taking the 1 mL working solution as an example, add 50 μL of 8.2 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	329.82	Formula	C₁₈H₁₉N₃O.HCl	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	99614-01-4	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	GR 38032F,SN 307			SMILES	CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C.Cl

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	5-HT3
In vivo	Ondansetron decreases the intensity of withdrawal signs such as increased defecation, jumping and wet-dog shakes, elevated the nociceptive threshold values which are decreased by precipitated withdrawal, but produces no change in urination, rectal temperature or salivation. Ondansetron and granisetron significantly enhances gastric emptying of glass beads and improves cisplatin-induced slowing of gastric emptying in rats. Ondansetron exhibits a biphasic dose-response profile in mice, with antidepressant-like effects peaking at 0.1 mg/kg, in the forced swim and tail suspension tests. Ondansetron pretreatment augments the antidepressant effects of fluoxetine and venlafaxine but does not influence the effects of desipramine or 8-hydroxy-2-(di-n-propylamino) tetralin. Ondansetron (10 mg/kg) reverses hyperactivity in the open field, and decreases the percentage entry and time spent in open arms in the elevated plus maze. Ondansetron, a selective and potent 5HT3 receptor antagonist, is shown to be effective at blocking the amphetamine-induced disruption of LI at a dose of 0.01 mg/kg, but not at 0.1 mg/kg. Ondansetron is able to attenuate increases in dopamine activity, produces pharmacologically with amphetamine without affecting baseline dopamine activity. Ondansetron facilitates performance in young adult and aged animals, and inhibits an impairment in habituation induced by scopolamine, electrolesions or ibotenic acid lesions of the nucleus basalis magnocellularis. Ondansetron and arecoline antagonizes a scopolamine-induced impairment.
References	[1] https://pubmed.ncbi.nlm.nih.gov/9537805/ [2] https://pubmed.ncbi.nlm.nih.gov/8699628/ [3] https://pubmed.ncbi.nlm.nih.gov/18195592/ [4] https://pubmed.ncbi.nlm.nih.gov/7855229/ [5] https://pubmed.ncbi.nlm.nih.gov/2140610/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-08-20)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07777276	NOT_YET_RECRUITING	Postoperative Sleep Quality; Postoperative Behaviour; Postoperative Recovery in Children; Postoperative Nausea and Vomiting (PONV); Paediatric Surgery; Anaesthesia	Telethon Kids Institute	2026-08-17	PHASE4
NCT07588217	NOT_YET_RECRUITING	ARDS (Acute Respiratory Distress Syndrome); Invasive Mechanical Ventilation; Patient-Self Inflicted Lung Injury	Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal	2026-10-01	PHASE2; PHASE3
NCT05784350	NOT_YET_RECRUITING	Intra-operative Hypotension	Meir Medical Center	2025-08-01
NCT03865290	RECRUITING	Indigestion; Diabetes Mellitus	Mayo Clinic	2019-04-02	PHASE2
NCT05844501	RECRUITING	Atrial Fibrillation	Indiana University	2025-04-22	PHASE4
NCT07795060	NOT_YET_RECRUITING	Cholera (Disorder)	Public Interest Science Center	2027-03-01	PHASE2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Ondansetron HCl 5-HT Receptor antagonist

Chemical Structure

Molecular Weight: 329.82